VistaGen Therapeutics, Inc (VTGN) Stock Price

0.6557 ▲ +0.0341 (+5.49%)
Open: 0.611 Vol: 869.98K Day's range: 0.61 - 0.664 May 13, 16:00 EDT
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
VTGN Technical Analysis
5 mins 30 mins Hourly Daily Weekly
BUY BUY BUY BUY BUY
  5 mins 30 mins Hourly Daily Weekly
MA5 0.65▲ 0.66▼ 0.65▲ 0.63▲ 0.62▲
MA10 0.66▲ 0.65▲ 0.64▲ 0.62▲ 0.60▲
MA20 0.65▲ 0.64▲ 0.65▲ 0.61▲ 0.60▲
MA50 0.64▲ 0.64▲ 0.62▲ 0.60▲ 2.14▼
MA100 0.64▲ 0.62▲ 0.61▲ 0.61▲ 2.53▼
MA200 0.63▲ 0.61▲ 0.60▲ 2.15▼ 3.43▼
  5 mins 30 mins Hourly Daily Weekly
MACD -0.001▼ 0.002▲ 0.001▲ 0.006▲ 0.092▲
RSI 58.109▲ 59.924▲ 59.579▲ 57.373▲ 33.330▼
STOCH 48.762     87.981▲ 90.271▲ 49.326     65.548    
WILL %R -31.148     -7.570▲ -5.013▲ -28.841     -15.468▲
CCI -12.090     77.410     114.839▲ 117.787▲ 139.797▲
Latest Filters Detected On VTGN
▼ GAP $VTGN Open Gap Down %5 Set Alert
▼ GAP $VTGN Open Gap Down %3 Set Alert
▼ GAP $VTGN Open Gap Down %2 Set Alert
CDL $VTGN Harami Candlestick Pattern Detected Set Alert
CDL $VTGN Doji Candlestick Pattern Detected Set Alert
VistaGen Therapeutics, Inc News
VistaGen Completes Phase 3 PALISADE-4 Trial Milestone
Sunday, May 10, 2026 10:52 AM
Detailed price information for Vistagen Therapeutics Inc (VTGN-Q) from The Globe and Mail including charting and trades.
Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
Friday, May 08, 2026 03:31 AM
The completion of the randomized portion of PALISADE-4 is another important step for our fasedienol Phase 3 program in social anxiety disorder, and we expect to announce topline results this quarter,” ...
Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Investor Alert: Schubert Jonckheer Investigating Possible False Claims Regarding Drug Candidate Following 80% Stock Drop
Monday, April 27, 2026 11:00 PM
SAN FRANCISCO, April 28, 2026 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises Vistagen Therapeutics, Inc. (NASDAQ: VTGN) investors that the firm is investigating potential legal claims arising ...
VTGN historical stock data
date open high low close volume
13/05/26 0.611 0.664 0.61 0.6557 869,977
12/05/26 0.6215 0.66 0.58 0.6216 6,312,197
11/05/26 0.61 0.697 0.61 0.6736 1,309,879
08/05/26 0.5974 0.638 0.5963 0.6105 1,172,060
07/05/26 0.61 0.61 0.58 0.5868 317,573
06/05/26 0.5995 0.6199 0.5866 0.6105 238,508
05/05/26 0.6267 0.6267 0.6002 0.6002 211,855
04/05/26 0.6251 0.666 0.6103 0.6225 605,604
01/05/26 0.6141 0.6355 0.6009 0.6258 427,119
30/04/26 0.60 0.6193 0.5851 0.6134 223,264
Quote Details
52wk Low:0.43
52wk High:5.14
Vol:869.98K
Avg Vol(3m):13.6M
1Y Chng:-74.59%
1M Chng:+9.17%
Add to Watch List
More Information
Index US Composite
Market Cap. 26.69M